Sumatriptan (intranasal route of administration) for acute migraine attacks in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2012, Pages

  Derry, Christopher J ^a   Derry, Sheena ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; SEROTONIN 1 AGONIST; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

ADULT; ANALGESIA; ASTHENIA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HEART PALPITATION; HUMAN; MALAISE; MIGRAINE; NAUSEA; NOSE DISEASE; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PARESTHESIA; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROAT DISEASE; VERTIGO; ACUTE DISEASE; FEMALE; INTRANASAL DRUG ADMINISTRATION; MALE; META ANALYSIS; METHODOLOGY;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; ADULT; DIHYDROERGOTAMINE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TRIAZOLES; TRYPTAMINES;

EID: 84861314069     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009663     Document Type: Review

References (56)

1. Glaxo Study No. S2B-T60. Cited in Dahlöf 1999, Table 1. Reference given as "Glaxo Study No. S2B-T60. Data on file with Glaxo Wellcome Research and Development". 3386700
2. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. International Journal of Clinical Practice 2000;54(5):281-6. [PUBMED: 10954953]3386699
3. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Archives of Family Medicine 1998;7(3):234-40. [DOI: 9596457]3386702
4. Djupesland PG, Docekal P, Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 2010;30(8):933-42. 3386704
5. Becker WJ. Glaxo Study No. S2B-T47. Cited in Dahlöf 1999, Table 1. Reference given as "Becker WJ, on behalf of the study group. A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. Philadelphia: Lippincott-Raven, 1997". 3386706
6. Peikert A, Becker WJ, Ashford EA, Dahlof C, Hassani H, Salonen RJ. Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. European Journal of Neurology 1999;6(1):43-9. 3386707
7. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997;49(5):1225-30. 3386709
8. A double-blind, placebo-controlled, parallel-group study to evaluate two dose levels (10 mg and 20 mg) of sumatriptan nasal spray in the acute treatment of a migraine attack with an optional repeat dose for headache recurrence. www.gsk-clinicalstudyregister.com/. 3386711
9. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. European Neurology 1991;31(5):332-8. 3386713
10. Salonen R, Ashford E, Dahlöf C, Dawson R, Gilhus NE, Lüben V, et al. International Intranasal Sumatriptan Study Group. Intranasal sumatriptan for the acute treatment of migraine. Journal of Neurology 1994;241(8):463-9. 3386715
11. A randomised double-blind, double-dummy, single-attack, parallel group study to compare the speed of onset of sumatriptan nasal spray (20 mg) with rizatriptan wafer (10 mg) in he acute treatment of migraine. www.gsk-clinicalstudyregister.com/. 3386717
12. Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. Journal of the Chinese Medical Association 2007;70(2):39-46. 3386719
13. Glaxo Study No. S2CM12. Cited in Dahlöf 1999, Table 1. Reference given as "Glaxo Study No. S2CM12. Data on file with Glaxo Wellcome Research and Development". 3386721
14. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559-66. [DOI: 10.1212/01.wn1.0000323925.29520.e7]
15. Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. Quarterly Journal of Medicine 1996;89(1):77-84.
16. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
17. Dahlöf C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999;19(9):769-78.
18. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews (forthcoming).
19. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008615]
20. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009665]
21. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009663]
22. Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009664]
23. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63. [DOI: 10.1111/j.1526-4610.2006.00631.x]
24. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Canadian Journal of Neurological Sciences 1993;20(2):131-7.
25. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13(6):667-76.
26. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58. [DOI: 10.1046/j.1468-2982.2002.00404.x]
27. Gendolla A. Early treatment in migraine: how strong is the current evidence?. Cephalalgia 2008;28 Suppl 2:28-35.
28. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends in Molecular Medicine 2007;13(1):39-44. [DOI: 10.1016/j.molmed.2006.11.005]
29. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health 2009;12(1):55-64. [DOI: 10.1111/j.1524-4733.2008.00404.x]
30. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Archives of Internal Medicine 1999;159(8):813-8.
31. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96.
32. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20(9):765-86.
33. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:1-160.
34. Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66(2-3):239-46.
35. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
36. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. Journal of Family Practice 1996;42(1):36-42.
37. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
38. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 1999;39 Suppl 2:S20-6.
39. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9.
40. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Archives of Internal Medicine 1999;159(8):857-63.
41. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46(5):715-25. [DOI: 10.1111/j.1526-4610.2006.00430.x]
42. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002915]
43. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16.
44. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24.
45. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ''Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150:386-9.
46. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50-63.
47. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-57.
48. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34(6):337-43.
49. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002;42 Suppl 1:10-7. [DOI: 10.1046/j.1526-4610.2002.0420s1010.x]
50. Anonymous. Prescription cost analysis, England 2010. The NHS Information Centre, Prescribing Support Unit 2011. [ISBN: 978-1-84636-542-3]
51. Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache 2009;49(1):79-89. [DOI: 10.1111/j.1526-4610.2008.01263.x]
52. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
53. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics 1997;11 Suppl 1:1-10.
54. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain 2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0]
55. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate results on meta-analysis: a case study. BMJ 1997;315(7109):635-40.
56. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30(9):1065-72. [DOI: 10.1177/0333102409355601]